Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Last trade$71.02
Day change-$0.95 (-1.32%)
Day range$69.27 – $75.05
Volume97,643
Market cap$488M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$487.72M
Price / earnings
—
Price / book
3.84×
Price / sales
—
EV / sales
—
EV / EBITDA
-17.07×
Profitability
Earnings per share
-$3.04
Return on assets
-15.82%
Return on equity
-16.21%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
43.55×
Quick ratio
43.55×
Cash ratio
17.65×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.27M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MNPR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.03M
$1.88M
$1.74M
$2.21M
$1.5M
$1.5M
$1.58M
$1.15M
Research and development
$4.44M
$4.77M
$3.49M
$3.94M
$2.59M
$1.73M
$1.64M
$9.92M
Total operating expenses
$7.47M
$6.64M
$5.23M
$6.16M
$4.09M
$3.23M
$3.22M
$11.07M
Operating income
-$7.47M
-$6.64M
-$5.23M
-$6.16M
-$4.09M
-$3.23M
-$3.22M
-$11.07M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$6.2M
-$5.31M
-$3.89M
-$5.2M
-$3.44M
-$2.45M
-$2.62M
-$10.93M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.2M
-$5.31M
-$3.89M
-$5.2M
-$3.44M
-$2.45M
-$2.62M
-$10.93M
Net income attributable to common shareholders
-$6.2M
-$5.31M
-$3.89M
-$5.2M
-$3.44M
-$2.45M
-$2.62M
-$10.93M
EBITDA
-$7.47M
-$6.64M
-$5.23M
-$6.16M
-$4.09M
-$3.23M
-$3.22M
-$11.07M
Basic earnings per share
-$0.72
-$0.62
-$0.46
-$0.61
-$0.48
-$0.35
-$0.38
-$2.21
Diluted earnings per share
-$0.72
-$0.62
-$0.46
-$0.61
-$0.48
-$0.35
-$0.38
-$2.21
Recent news
Company coverage with links to the original publishers.
Monopar Therapeutics announced Phase 2 trial results for ALXN1840 (tiomolibdate choline) in treatment-experienced Wilson disease patients. The study demonstrated stabilization or improvement in liver pathology across multiple histologic measures, significant neurologic improvements in UWDRS scores, and improved quality of life. The drug was generally well tolerated with mostly Grade 1-2 adverse events.
Monopar Therapeutics announced Q1 2026 financial results with cash reserves of $137.5 million and a net loss of $3.9 million. The company presented Phase 3 FoCus trial data showing ALXN1840 (tiomolibdate choline) demonstrated greater neurologic benefit versus standard-of-care in Wilson disease patients. The NDA submission to the FDA remains on track for mid-2026, with new Chief Commercial and Strategy Officer Susan Rodriguez leading commercial readiness activities.
Monopar Therapeutics announced 2025 financial results with a net loss of $13.7 million and cash reserves of $140.4 million expected to support operations through at least December 2027. The company plans to submit a New Drug Application for ALXN1840 in mid-2026 for Wilson disease treatment, supported by positive clinical data presentations and FDA interactions. The company also strengthened its leadership team and balance sheet through a $91.9 million public offering.
Monopar Therapeutics presented new data at AASLD showing that ALXN1840 (tiomolybdate choline) rapidly improved copper balance in Wilson disease patients through increased fecal copper excretion.
Monopar Therapeutics is conducting a $135 million underwritten offering of common stock and pre-funded warrants, with plans to use proceeds for general corporate purposes and a stock repurchase from Tactic Pharma.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.